Table 3. Descriptive statistics of serum GFAP measurements (pg/mL) in patients without optic nerve disease1 are shown.
| NMO (pg/mL) | ‘RION’ (pg/mL) | ‘CRION’ (pg/mL) | R+C (pg/mL) | |
| Mean | 6.46 | 2.71 | 3.16 | 2.94 |
| Std Dev1 | 4.68 | 2.28 | 2.29 | 2.22 |
| C.I. of Mean2 | 4.91 | 1.91 | 1.91 | 1.18 |
| Median | 5.76 | 2.58 | 2.56 | 2.58 |
| 25% | 3.30 | 0.80 | 1.46 | 0.95 |
| 75% | 7.21 | 4.16 | 4.39 | 4.39 |
| Skewness | 1.45 | 0.62 | 1.08 | 0.75 |
| Kurtosis | 2.72 | −0.45 | 1.12 | −0.09 |
| 99% C.I.3 | 7.70 | 2.82 | 2.83 |
AQP4+ON patients showed the highest levels of serum GFAP as well as the highest variance. Both the median and mean values for serum GFAP level are higher in AQP4+ON patients compared to the values in the NMO spectrum group as a whole (4.63 pg/mL, 5.90 pg/mL). All values are stated to within 2 decimal places.
1
Std Dev = standard deviation.
2
C.I. = Confidence Interval.
3
ON = optic neuritis, AQP4+ON = Aquaporin 4 autoantibody positive ON, ‘CRION’ = ‘chronic relapsing inflammatory optic neuropathy’, ‘RION’ = Recurrent Isolated Optic Neuritis.